iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees95
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable
iCAD (NASDAQ:ICAD) Frequently Asked Questions
What is iCAD's stock symbol?
iCAD trades on the NASDAQ under the ticker symbol "ICAD."
How were iCAD's earnings last quarter?
iCAD Inc (NASDAQ:ICAD) posted its earnings results on Wednesday, October, 30th. The technology company reported ($0.10) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.10). The technology company had revenue of $7.86 million for the quarter, compared to analysts' expectations of $7.43 million. View iCAD's Earnings History.
When is iCAD's next earnings date?
How can I listen to iCAD's earnings call?
iCAD will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for ICAD?
4 equities research analysts have issued 12 month price objectives for iCAD's stock. Their forecasts range from $10.00 to $15.00. On average, they expect iCAD's share price to reach $13.50 in the next year. This suggests a possible upside of 12.7% from the stock's current price. View Analyst Price Targets for iCAD.
What is the consensus analysts' recommendation for iCAD?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for iCAD.
Has iCAD been receiving favorable news coverage?
Headlines about ICAD stock have been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. iCAD earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for iCAD.
Are investors shorting iCAD?
iCAD saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 682,400 shares, an increase of 13.4% from the December 31st total of 601,500 shares. Based on an average trading volume of 102,800 shares, the days-to-cover ratio is presently 6.6 days. Approximately 4.0% of the shares of the stock are short sold. View iCAD's Current Options Chain.
What other stocks do shareholders of iCAD own?
Who are iCAD's key executives?
iCAD's management team includes the folowing people:
- Ms. Stacey M. Stevens, Pres (Age 51)
- Mr. Michael S. Klein, Exec. Chairman & CEO (Age 65)
- Mr. R. Scott Areglado, VP, Corp. Controller & Interim CFO (Age 55)
- Mr. Jonathan Go, Chief Technology Officer (Age 56)
- Ms. Annette L. Heroux, VP of Admin. (Age 62)
Who are iCAD's major shareholders?
iCAD's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.11%), Parkman Healthcare Partners LLC (3.10%), EAM Investors LLC (1.81%), Oxford Asset Management LLP (0.59%), Essex Investment Management Co. LLC (0.45%) and Acadian Asset Management LLC (0.44%). View Institutional Ownership Trends for iCAD.
Which institutional investors are selling iCAD stock?
ICAD stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Granite Investment Partners LLC, Oxford Asset Management LLP, Advisor Group Inc., Acadian Asset Management LLC and Sprott Inc.. View Insider Buying and Selling for iCAD.
Which institutional investors are buying iCAD stock?
ICAD stock was acquired by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Credit Suisse AG, Schonfeld Strategic Advisors LLC, EAM Investors LLC, Charles Schwab Investment Management Inc., Renaissance Technologies LLC and California Public Employees Retirement System. View Insider Buying and Selling for iCAD.
How do I buy shares of iCAD?
Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is iCAD's stock price today?
One share of ICAD stock can currently be purchased for approximately $11.98.
MarketBeat Community Rating for iCAD (NASDAQ ICAD)
MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
